Evaluation of HZX-960, a Novel DCN1-UBC12 Interaction Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis

Researchers identified that HZX-960 treatment could attenuate TGFβ-induced liver fibrotic responses by reducing the deposition of collagen I and α-SMA, and upregulating cellular NRF2, HO-1 and NQO1 level in two hepatic stellate cell lines.